Epidemiology of pediatric sarcoma in Iran

Mehdi Azizmohammad Looha1, Atieh Akbari2, Mohammad Esmaeil Akbari3

  • 1Biostatistics, Pediatric Pathology Research Center, Research Institute for Children's Health, Tehran, Iran.

Insights

This study found lower incidence and survival rates for pediatric soft-tissue sarcomas (STSs) and malignant bone tumors (MBTs) in Iran compared to high-income countries. Improving cancer registries is crucial for better sarcoma prevention and control.

Area of Science:

  • Pediatric oncology
  • Cancer epidemiology
  • Sarcoma research

Background:

  • Pediatric sarcomas encompass soft-tissue sarcomas (STSs) and malignant bone tumors (MBTs).
  • Understanding the epidemiology of these rare cancers is vital for public health initiatives.

Purpose of the Study:

  • To determine the incidence and survival rates of pediatric STSs and MBTs in Iran.
  • To analyze these rates based on diagnosis date, gender, age, and histological types.
  • To compare Iranian data with international benchmarks.

Main Methods:

  • Utilized data from the Iran National Cancer Registry (2008-2015).
  • Classified cases according to the International Classification of Childhood Cancer (3rd ed.).
  • Calculated age-standardized incidence rates (ASIRs) and five-year survival rates for available data.

Main Results:

  • Survival data was available for only 21% of pediatric sarcoma cases.
  • Incidence and survival rates for MBTs and STSs in Iran were lower than in high-income countries.
  • Survival rates for these malignancies were significantly lower in Iran compared to high-income nations.

Conclusions:

  • This is the first comprehensive study on pediatric sarcomas in Iran.
  • The findings highlight disparities in incidence and survival rates compared to high-income countries.
  • There is an urgent need to enhance the quality and quantity of Iran's population-based cancer registries for improved sarcoma management.
Abstract

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
442
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
777
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
49.4K